Sana Biotechnology Inc is at the forefront of biotechnology, focusing on turning engineered cells into innovative medicines. The company is pioneering in areas such as oncology, diabetes, and central nervous system disorders, aiming to address unmet treatment needs. With a robust pipeline including therapies for hematologic malignancies, non-Hodgkin’s lymphoma, multiple autoimmune disorders, and diabetes, Sana is leveraging cutting-edge technologies like CRISPR for cell therapy product development. Founded in 2018 and based in Seattle, Washington, Sana is committed to transforming the therapeutic landscape.
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
